Takeda has partnered with Point32Health in a new value-based oncology program. Alunbrig, used in non-small cell lung cancer, is the first drug offered through the pilot project; if successful, Takeda promises to expand the program.
Takeda Oncology’s Dion Warren remarks, “We need to learn through this experience and continue to broaden our approach to access so we can benefit as many patients as possible,” adding, “This is the first for us—it’s not going to be the last.” Read more here.
(Source: Angus Liu, 11/8/21)
